Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin Cancer/MelanomaSkin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin Cancer/MelanomaSkin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

News

Article

May 28, 2025

Phase 1/2 Trial Investigating ATR-04 for EGFRi-Related Rashes in Lung Cancer

Author(s):

Ryan Scott

Fact checked by:

Spencer Feldman

Key Takeaways

  • ATR04-484 is a live biotherapeutic product targeting EGFR inhibitor-associated rashes in cancer patients, containing a modified Staphylococcus epidermidis strain.
  • EGFR inhibitors, used in treating several cancers, often cause dermatologic toxicities, leading to treatment discontinuation and patient discomfort.
  • The ATR04-484 trial's findings will be presented at the 2025 ASCO Annual Meeting, highlighting its potential impact on managing EGFR inhibitor-induced skin toxicities.
  • The FDA has granted Fast Track designation to ATR04-484, emphasizing its potential importance in improving cancer treatment outcomes.
SHOW MORE

ATR-04 therapy is being investigated in the phase 1/2 ATR04-484 clinical trial for the treatment of EGFR inhibitor-associated rashes in lung cancer.

Image of lungs.

A trial is investigating ATR-04 to treat EGFR inhibitor-related rashes in lung cancer.

The phase 1/2 ATR04-484 clinical trial is examining ATR-04 therapy for the treatment of EGFR inhibitor-associated rashes in patients with non-small cell lung cancer, colorectal cancer and others, according to a news release from Azitra, Inc., a clinical stage biopharmaceutical company.

The news release went on to note that data derived from the investigation will be shared at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO) being held May 30 to June 3, 2025, in Chicago, Illinois.

“We believe topical ATR04-484 has the potential to be an important advance in the treatment of EGFR inhibitor-associated skin rash, which is a painful and debilitating condition that often leads patients to suspend use of these life-saving cancer therapies,” Dr. Mary Spellman, chief medical officer of Azitra, said in the news release.

“As we prepare to dose the first patient in the phase 1/2 clinical trial of ATR04-484, we are excited to present an overview of the study at [the] 2025 ASCO Annual Meeting, which is the preeminent global oncology meeting. The product represents a unique and novel method for treating EGFR inhibitor-associated skin toxicities, and we look forward to presenting this technology to leaders in the cancer research community.”

The presentation is entitled "Epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity treated with topical application of a novel Staphylococcus epidermidis compound," and will feature the multicenter, randomized, double-blind, vehicle-controlled phase 1/2 study. The safety and tolerability of ATR04-484 will be examined throughout the clinical investigation for the treatment of EGFR inhibitor-induced dermal toxicity in adult patients.

ATR04-484, the agent being studies, is a live biotherapeutic product candidate that contains a naturally derived Staphylococcus epidermidis strain. To enhance safety, an antibiotic resistance gene was deleted, and auxotrophy was engineered to regulate its growth.

Moreover, Azitra has received Fast Track designation from the FDA for ATR04-484 in the treatment of rash associated with EGFR inhibitors.

Dr. Mary Spellman, chief medical officer, will present the information in a poster at the 2025 ASCO Meeting, taking place at McCormick Place in Chicago. Her presentation will be part of the Symptom Science and Palliative Care track. The poster, designated as number 162b, will highlight relevant findings from the investigation.

What are EGFR Inhibitors, and who can be Treated With Them?

Epidermal growth factor receptor (EGFR) inhibitor therapies, like small-molecule kinase inhibitors and monoclonal antibodies, are standard therapeutic approaches for several cancers, such as non-small cell lung cancer, colorectal cancer, pancreatic cancer, breast cancer and squamous cell carcinoma of the head and neck, according to the National Library of Medicine. Despite significantly prolonged progression-free survival with these therapies, due to intrinsic and/or acquired resistance, curative effects are not often achieved.

The news release goes on to say that EGFR inhibitor therapies work by blocking the activity of the EGFR protein, which is important because this protein plays a vital role in cell growth and survival. However, these treatments are also associated with specific side effects, such as dermatologic toxicities, which can affect treatment efforts and cause physical and psychological discomfort for patients. Due to these side effects, some patients may reduce or even stop these effective treatments.

More Information on EGFR Inhibitor-Induced Skin Toxicities

EGFR inhibitors — including drugs like Erbitux (cetuximab), Vectibix (panitumumab), Tarceva (erlotinib) and Iressa (gefitinib) — are effective cancer therapies but are commonly associated with inflammatory skin rashes, the most frequent side effects associated with the use of EGFR-inhibitors. These acneiform or rosacea-like eruptions typically appear within days to weeks of treatment, affecting over 90% of patients.

The rash often begins within areas of skin that bear high densities of seborrheic glands, though it can spread or develop into perifollicular xanthomas. Notably, recent studies have noted that rash appearance and severity has been linked to improved tumor response.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors and text.
Image of 2 doctors and text.
Image of two doctors and text.
Image of man.
Image of doctor.
Image of Dr. Boffa.
Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.
Image of Dr. Reznick
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Related Content
Advertisement
Image of lung.
June 18th 2025

Recent SCLC Data May Impact How Patients Are Treated Day-to-Day

Ryan Scott
Various trials within the small cell lung cancer space were brought to light following recent data, impacting how patients will be treated in the future.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of Sue.
June 16th 2025

Cancer Recurrence, Getting Past the Anxiety

Sue McCarthy
If there is ever an annual follow up CT scan that does not cause me significant anxiety, this year will be the one.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of two doctors with text.
June 13th 2025

Updates in Shared Decision-Making in Lung Cancer Following ASCO 2025

Ryan Scott
Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.
The U.S. FDA has approved treatment with Ibtrozi patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
June 11th 2025

FDA Approves Ibtrozi for ROS1+ Advanced Non-Small Cell Lung Cancer

Spencer Feldman
The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Related Content
Advertisement
Image of lung.
June 18th 2025

Recent SCLC Data May Impact How Patients Are Treated Day-to-Day

Ryan Scott
Various trials within the small cell lung cancer space were brought to light following recent data, impacting how patients will be treated in the future.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of Sue.
June 16th 2025

Cancer Recurrence, Getting Past the Anxiety

Sue McCarthy
If there is ever an annual follow up CT scan that does not cause me significant anxiety, this year will be the one.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of two doctors with text.
June 13th 2025

Updates in Shared Decision-Making in Lung Cancer Following ASCO 2025

Ryan Scott
Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.
The U.S. FDA has approved treatment with Ibtrozi patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
June 11th 2025

FDA Approves Ibtrozi for ROS1+ Advanced Non-Small Cell Lung Cancer

Spencer Feldman
The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.